DDrare: Database of Drug Development for Rare Diseases

Searched query = "Eosinophilic granulomatosis with Polyangiitis", "EGPA", "Eosinophilic multiple vasculitis granulomatous disease", "Allergic granulomatous angiitis", "Churg-Strauss syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Anti-thymocyte globulin; Azathioprine; Benralizumab; CYCLOPHOSPHAMIDE; Corticosteroid; Corticosteroid and azathioprine; Cyclophosphamide; Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; Cyclosporine; Filgrastim; Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS); HPC cell infusion; Human normal immunoglobulin; Hydroxychloroquine; Infliximab; L04AC06; MEDI-563; MEPOLIZUMAB; MESNA; Mepolizumab; Mesna; Methotrexate; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Mycophenolate mofetil,methotrexate; NUCALA; Naltrexone; Naltrexone Hydrochloride; Nucala; Nucala 100 mg powder for solution for injection; Placebo (physiological saline); Plaquenil - Hydroxychloroquine 200mg Film coated tablets; Prednisolone; Prednisone; Prednisone, methylprednisolone,cyclophosphamides; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; RITUXIMAB; Rituximab; SB-240563; SB-240563 (mepolizumab)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001832-77-DE (EUCTR)	15/01/2020	21/08/2019	Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.	A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in patients receiving Standard of Care Therapy	Eosinophilic Granulomatosis with Polyangiitis (EGPA) MedDRA version: 20.1;Level: LLT;Classification code 10014957;Term: Eosinophilic granulomatous vasculitis;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: Benralizumab Trade Name: Nucala 100 mg powder for solution for injection Product Name: mepolizumab Product Code: L04AC06 INN or Proposed INN: Mepolizumab Other descriptive name: Nucala	AstraZeneca AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	United States;France;Canada;Belgium;Israel;Germany;United Kingdom;Japan;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-001832-77-DE
(EUCTR)

15/01/2020

21/08/2019

Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab.

A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in patients receiving Standard of Care Therapy

Eosinophilic Granulomatosis with Polyangiitis (EGPA)
MedDRA version: 20.1;Level: LLT;Classification code 10014957;Term: Eosinophilic granulomatous vasculitis;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Product Name: benralizumab
Product Code: MEDI-563
INN or Proposed INN: benralizumab
Other descriptive name: Benralizumab
Trade Name: Nucala 100 mg powder for solution for injection
Product Name: mepolizumab
Product Code: L04AC06
INN or Proposed INN: Mepolizumab
Other descriptive name: Nucala

AstraZeneca AB

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

140

Phase 3

United States;France;Canada;Belgium;Israel;Germany;United Kingdom;Japan;Italy